

Advancing Biomedical Science Through Tissue Amage

Cat No: **BRC961 – Breast cancer tissue array**

anti- n

Recommended applications: For Research use only. RNA or protein breast cancer/non-tumor tissue profiling using IHC or ISH; Antibody characterization.

Description: Breast cancer tissue array for replacement of BRC961, 96 cores, including 36 cases (purple/blue) of breast cancers and 12 cases of normal, reactive and benign tumor tissues of the breast (pink) in duplicates.

All the tissues were from surgical resection. They were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or APES coated Superfrost slides. They can be stored for use at 4C for up to six months from the date of shipment. **There may be 5 to 10% of tissue core loss**. Because of their tiny sizes, normal breast glands may run out.

Array Position	Sex	Age	Anatomic Site	Pathology	Grade	Stage
A01	F	50	Breast	Normal	null	null
A02	F	43	Breast	Normal	null	null
A03	F	50	Breast	Normal	null	null
A04	F	30	Breast	Normal	null	null
A05	F	52	Breast	Blunt duct adenosis	null	null
A06	F	38	Breast	Blunt duct adenosis	null	null
A07	F	41	Breast	Fibrocystic changes	null	null
A08	F	40	Breast	Fibrocystic changes	null	null
A09	F	41	Breast	Fibrocystic changes	null	null
A10	F	39	Breast	Fibroadenoma	null	null
A11	F	16	Breast	Fibroadenoma	null	null
A12	F	34	Breast	Fibroadenoma	null	null
B01	F	50	Breast	Normal	null	null
B02	F	43	Breast	Normal	null	null
B03	F	50	Breast	Normal	null	null
B04	F	30	Breast	Normal	null	null
B05	F	52	Breast	Blunt duct adenosis	null	null
B06	F	38	Breast	Blunt duct adenosis	null	null
B07	F	41	Breast	Fibrocystic changes	null	null
B08	F	40	Breast	Fibrocystic changes	null	null
B09	F	41	Breast	Fibrocystic changes	null	null
B10	F	39	Breast	Fibroadenoma	null	null
B11	F	16	Breast	Fibroadenoma	null	null
B12	F	34	Breast	Fibroadenoma	null	null
C01	F	38	Breast	Phyllodes sarcoma	null	null
C02	F	52	Breast	Ductal carcinoma in situ	I	TisN0M0
C03	F	33	Breast	Ductal carcinoma in situ	Ι	TisN0M0
C04	F	37	Breast	Invasive ductal carcinoma	Ι	T3N1M0
C05	F	53	Breast	Ductal carcinoma in situ	I	TisN0M0
C06	М	61	Breast	Ductal carcinoma in situ, papillary	I~II	TisN0M0
C07	F	41	Breast	Invasive ductal carcinoma	I~II	T2N0M0
C08	F	55	Breast	Invasive ductal carcinoma	II	T3N1M0
C09	F	44	Breast	Invasive ductal carcinoma	II~III	T4N2M0
C10	F	72	Breast	Invasive ductal carcinoma	II	T2N0M0
C11	F	41	Breast	Invasive ductal carcinoma	II~III	T3N1M0



Phone: 415-863-2380 Support: <u>info@pantomics.com</u> Web: www.pantomics.com

		Advanc	ng Biomedical S	cience Through Tissus Arrays		
C12	l F	18	Breast	Invasive ductal carcinoma	II~III	T2N1M0
D01	F	38	Breast	Phyllodes sarcoma	null	null
D02	F	52	Breast	Ductal carcinoma in situ	I	TisN0M0
D03	F	33	Breast	Ductal carcinoma in situ	I	TisN0M0
D04	F	37	Breast	Invasive ductal carcinoma	I	T3N1M0
D05	F	53	Breast	Ductal carcinoma in situ	I	TisN0M0
D06	M	61	Breast	Ductal carcinoma in situ, papillary	I~II	TisN0M0
D07	F	41	Breast	Invasive ductal carcinoma	I~II I~II	T2N0M0
D08	F	55	Breast	Invasive ductal carcinoma	II	T3N1M0
D09	F	44	Breast	Invasive ductal carcinoma	II~III	T4N2M0
D10	F	72	Breast	Invasive ductal carcinoma	II	T2N0M0
D11	F	41	Breast	Invasive ductal carcinoma	II~III	T3N1M0
D12	F	18	Breast	Invasive ductal carcinoma	II~III II~III	T2N1M0
E01	F	31	Breast	Invasive ductal carcinoma	II~III II~III	T4N1M0
E02	F	54	Breast	Invasive ductal carcinoma	II~III II~III	T2N0M0
E03	F	75	Breast	Invasive ductal carcinoma	III	T3N0M0
E04	F	30	Breast	Invasive ductal carcinoma, tubular type	In I~II	T3N0M0
E05	F	43	Breast	Invasive ductal carcinoma, tubular type	III	T3N0M0
E06	F	37	Breast	Invasive ductal carcinoma	III II~III	T2N1M0
E07	F	42	Breast	Invasive ductal carcinoma	II	T4N1M0
E08	F	30	Breast	Invasive ductal carcinoma	III	T2N0M0
E09	F	39			III II~III	T4N0M0
E09 E10	F	46	Breast	Invasive ductal carcinoma Invasive ductal carcinoma	II~III	T3N1M0
			Breast			
E11	F	40	Breast	Invasive ductal carcinoma	II~III	T3N1M0
E12	F	58	Breast	Invasive ductal carcinoma	II	T3N0M0
F01	F	31	Breast	Invasive ductal carcinoma	II~III	T4N1M0
F02	F	54	Breast	Invasive ductal carcinoma	II~III	T2N0M0
F03	F	75	Breast	Invasive ductal carcinoma	III	T3N0M0
F04	F	30	Breast	Invasive ductal carcinoma, tubular type	I~II	T3N0M0
F05	F	43	Breast	Invasive ductal carcinoma	III	T3N0M0
F06	F	37	Breast	Invasive ductal carcinoma	II~III	T2N1M0
F07	F	42	Breast	Invasive ductal carcinoma	II	T4N1M0
F08	F	30	Breast	Invasive ductal carcinoma	III	T2N0M0
F09	F	39	Breast	Invasive ductal carcinoma	II~III	T4N0M0
F10	F	46	Breast	Invasive ductal carcinoma	II	T3N1M0
F11	F	40	Breast	Invasive ductal carcinoma	II~III	T3N1M0
F12	F	58	Breast	Invasive ductal carcinoma	II	T3N0M0
G01	F	35	Breast	Invasive ductal carcinoma	II	T2N0M0
G02	F	53	Breast	Invasive ductal carcinoma	II	T2N0M0
G03	F	50	Breast	Invasive ductal carcinoma	II	T3N1M0
G04	F	48	Breast	Invasive ductal carcinoma	II~III	T2N1M0
G05	F	51	Breast	Invasive ductal carcinoma	II	T4N1M0
G06	F	43	Breast	Invasive ductal carcinoma	II	T4N1M0
G07	F	43	Breast	Invasive ductal carcinoma	II	T3N1M0
G08	F	40	Breast	Invasive ductal carcinoma	II	T2N0M0
G09	F	47	Breast	Invasive ductal carcinoma	I~II	T3N1M0
G10	F	49	Breast	Invasive ductal carcinoma	II	T3N1M0
G11	F	58	Breast	Mucinous adenocarcinoma	null	T3N0M0
G12	F	40	Breast	Invasive lobular carcinoma	Ι	T2N1M0
H01	F	35	Breast	Invasive ductal carcinoma	II	T2N0M0
H02	F	53	Breast	Invasive ductal carcinoma	II	T2N0M0
H03	F	50	Breast	Invasive ductal carcinoma	II	T3N1M0
H04	F	48	Breast	Invasive ductal carcinoma	II~III	T2N1M0
H05	F	51	Breast	Invasive ductal carcinoma	II	T4N1M0
H06	F	43	Breast	Invasive ductal carcinoma	II	T4N1M0
H07	F	43	Breast	Invasive ductal carcinoma	II	T3N1M0
H08	F	40	Breast	Invasive ductal carcinoma	II	T2N0M0
H09	F	47	Breast	Invasive ductal carcinoma	I~II	T3N1M0
C		1	1			-



Phone: 415-863-2380 Support: <u>info@pantomics.com</u> Web: www.pantomics.com

Advancing Biomedical Science Through Tissue Array						
H10	F	49	Breast	Invasive ductal carcinoma	II	T3N1M0
H11	F	58	Breast	Mucinous adenocarcinoma	null	T3N0M0
H12	F	40	Breast	Invasive lobular carcinoma	Ι	T2N1M0

Notes: Bake at 60C for ~60 minutes before use. If antigen retrieving is needed, it is important to avoid **direct-boiling and high pH or high strength** antigen retrieving buffer. For availability of complimentary IHC data, please contact us at info@pantomics.com.

Certified by: Fancai Li, M.D.

TNM Classification: Breast carcinoma

T- Primary tumor

- TX Primary tumor cannot be assessed
- TO No evidence of primary tumor
- Tis Carcinoma in situ, intraductal carcinoma or lobular carcinoma in situ, or Paget's disease of the nipple with no tumor
- T1 Tumor 2 cm or less in greatest dimension
- T2 Tumor more than 2 cm but not more than 5 cm in greatest dimension
- T3 Tumor more than 5 cm in greasiest dimension
- T4 Tumor of any size with direct extension to chest wall or skin

N - Regional lymph nodes

- NX Regional lymph nodes cannot be assessed
- NO No regional lymph node metastasis
- N1 Metastasis to movable ipsilateral lymph node(s)
- N2 Metastasis to ipsilateral lymph nodes(s) fixed to one another or to other structure
- N3 Metastasis to ipsilateral internal mammary lymph node(s)

M - Distant metastasis

- MX Distant metastasis cannot be assessed
- MO No distant metastasis
- M1 Distant metastasis

TNM classification of malignant tumours, Fifth Edition (1997)